Skip to content
Buy This GLP
← Research
Evidence

What Semaglutide Doses Did Danish Pharmacy Users Report?

In a Danish pharmacy survey, 45% of respondents reported taking 1 mg of semaglutide and 8% expected to reach 2.4 mg.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read
Danish pharmacy survey, 767 people buying semaglutidecurrently on 1 mg45%expect to reach 2.4 mg8%Current doses and future expectations were self-reported.And 10% said they dose by counting clicks on the pen.

Well below the label dose. In a survey of 767 Danish adults collecting a semaglutide weight-management prescription, 45% were currently taking 1 mg and only 8% expected ever to reach the 2.4 mg label dose. Ten percent reported dosing by counting clicks on the pen, against official prescribing guidance.

A separate study of tirzepatide refills reported that most participants were still below 10 mg at the sixth fill [2]. For either drug, compare the total at your prescribed dose and ask what would change if your prescriber adjusts it.

The single-practice semaglutide study tracked doses and treatment interruptions over time. This pharmacy survey asked 767 respondents what they took and what they expected to take. About 45% reported taking 1 mg at the time of the survey, and 8% expected to reach 2.4 mg [1].

At one to three months, the median self-reported weight loss was 6% (IQR 3% to 7%). Beyond a year, it was 20% (IQR 15% to 26%). Median loss was 12% at three to six months and 17% at six to twelve months [1]. Among people on 1 mg the figures were similar. The survey did not assign doses or compare their effects under controlled conditions. A randomized tirzepatide maintenance trial compared continuing treatment, lowering the dose and switching to placebo after initial weight loss. Its results apply to the specific tirzepatide regimens studied.

Ten percent reported counting clicks on their injection pen, a practice the authors say differs from official instructions [1]. The survey did not verify the amount those respondents injected.

Twenty-four percent reported reducing or stopping another medication after starting semaglutide [1]. Common categories among those reporting changes included medications for muscle or joint pain (30%) and blood pressure (24%). The survey recorded changes reported by patients. It did not measure prescription savings.

Among 42 first-time users in a separate six-month follow-up, 83% reported still using semaglutide [1]. The guide to prepaying for a GLP-1 uses larger studies to put treatment discontinuation in context. Before paying for six months, check the refund terms if you stop early.

Frequently asked

What dose are most people actually on?
In this survey, 45% were taking 1 mg and only 8% expected ever to reach the 2.4 mg weight-management dose. Self-reported results among 1 mg users were similar to the cohort overall.
Do the weight loss figures show what happens over a year?
No. They come from different people answering at one point in time, so the longer-duration figures describe people who were still taking the drug — not a group followed from the start.
Did people stop other medications?
Twenty-four percent reported reducing or discontinuing another medication, most often for muscle or joint pain (30%) and blood pressure (24%).

Sources

  1. [1] Kjærgaard K, Graabæk T, Thomsen RW, Cardél LG, Bramming M, Pottegård A, Lundby C (2026). Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey Diabetes, Obesity and Metabolism. PMID 42443134
  2. [2] Hankosky ER, et al. (2025). Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database Diabetes, Obesity and Metabolism. PMID 39996368

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence